Valuation: Laboratorios Farmaceuticos Rovi, S.A.

Market Cap 294.11Cr 336.59Cr 270.07Cr 251.86Cr 477.47Cr 32TCr 485.53Cr 3.25TCr 1.26TCr 16TCr 1.26TCr 1.24TCr 54TCr P/E 2026 *
22x
P/E 2027 * 16.6x
Enterprise Value 291.32Cr 333.4Cr 267.51Cr 249.47Cr 472.94Cr 32TCr 480.93Cr 3.22TCr 1.25TCr 16TCr 1.25TCr 1.22TCr 54TCr EV / Sales 2026 *
3.76x
EV / Sales 2027 * 3.18x
Free-Float
31.63%
Yield 2026 *
1.69%
Yield 2027 * 1.95%
3 years 50.88
Extreme 50.88
90.61
5 years 0.03
Extreme 0.03
90.61
10 years 0.03
Extreme 0.03
90.61
Manager TitleAgeSince
Chief Executive Officer - 27/07/2007
Director of Finance/CFO - 01/01/2001
Chief Tech/Sci/R&D Officer - 01/01/2014
Director TitleAgeSince
Chairman - 17/07/2021
Director/Board Member - 27/07/2007
Director/Board Member - 27/07/2007
Change 5-day change 1-year change 3-year change Capi.($)
-27.31%-.--% - - 334.98Cr
+1.57%+7.31%+55.29%+162.26% 1,06300Cr
+3.23%+7.12%+68.63%+60.58% 61TCr
+3.51%+6.83%+36.17%+92.39% 44TCr
+4.17%-0.96%+26.12%+20.22% 32TCr
+4.94%+3.39%+39.92%+40.14% 29TCr
+2.42%+1.60%+30.06%+44.59% 28TCr
+2.47%+5.18%-24.80%-38.67% 22TCr
+2.99%+5.59%+25.49%+65.56% 20TCr
+3.31%+5.14%+16.76%+69.72% 16TCr
Average +0.18%+2.83%+30.40%+57.42% 39.79TCr
Weighted average by Cap. +2.89%+4.16%+41.14%+82.76%

Financials

2026 *2027 *
Net sales 77Cr 89Cr 71Cr 66Cr 125.66Cr 8.43TCr 127.78Cr 855.79Cr 331.66Cr 4.14TCr 332.61Cr 325.38Cr 14TCr 90Cr 102.79Cr 82Cr 77Cr 145.82Cr 9.79TCr 148.28Cr 993.08Cr 384.87Cr 4.8TCr 385.96Cr 377.58Cr 17TCr
Net income 13Cr 15Cr 12Cr 11Cr 22Cr 1.45TCr 22Cr 147.03Cr 57Cr 710.65Cr 57Cr 56Cr 2.45TCr 18Cr 20Cr 16Cr 15Cr 29Cr 1.93TCr 29Cr 196.36Cr 76Cr 949.09Cr 76Cr 75Cr 3.27TCr
Net Debt -2.79Cr -3.19Cr -2.56Cr -2.39Cr -4.52Cr -303.66Cr -4.6Cr -31Cr -12Cr -148.94Cr -12Cr -12Cr -513.22Cr -8.59Cr -9.83Cr -7.89Cr -7.36Cr -14Cr -935.85Cr -14Cr -95Cr -37Cr -459.03Cr -37Cr -36Cr -1.58TCr
Logo Laboratorios Farmaceuticos Rovi, S.A.
Laboratorios Farmaceuticos Rovi, S.A. specializes in the research, development, manufacturing and marketing of biological medications and specialty drugs. Net sales break down by family of products as follows: - prescription pharmaceuticals (49%): intended for preventing and treating venous thrombo-embolic disease, post-menopausal osteoporosis, muscle pain, tooth and mouth infections, angina, osteoarthritis, etc.; - pharmaceutical products manufactured under contract (44%); - diagnostic products (7%): contrast products used in medical imaging with magnetic resonance, ultrasound, or X-rays. The group also offers hospital products and non-prescription pharmaceuticals. Net sales break down by source of revenue between sales of products (95.4%) and sales of services (4.6%). Net sales are distributed geographically as follows: Spain (77%), Italy (5%), Germany (3%), Portugal (2%), France (1%), Greece (1%) and other (11%).
Employees
1,998
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
57.50EUR
Average target price
75.38EUR
Spread / Average Target
+31.09%

Quarterly revenue - Rate of surprise